Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Md. and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Roger Jeffs , ... provide an overview and update on the company,s business at ... in Boston, Massachusetts . The ... 3:30 PM Eastern Time, and can be accessed via a ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
(Date:4/30/2015)... South San Francisco, CA (PRWEB) April 30, 2015 ... revenues for the first quarter of 2015 were $4.4 million, ... The net loss for the first quarter was $8.9 ... compared to a net loss for the same period in ... diluted share. As of March 31, 2015, cash, cash equivalents ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Support of Eradicating ,Drive-Through, ... to, Recuperate for at Least 48 Hours in the Hospital Following ... ... 18 "Desperate Housewives",star Marcia Cross will join Lifetime, Senator Landrieu (D-LA) ...
... a world leader in clinical,solutions for radiation therapy ... Elekta technology to implement clinical treatments with,Volumetric Modulated ... of,VMAT in Europe, the way has been cleared ... General Hospital Vienna in Austria to treat cancer ...
... Jan. 18 Derma Sciences, Inc.,(OTC Bulletin Board: DSCI), ... has increased its direct-sales staff significantly, based on a,number ... markets. The,company, which had only two direct salespersons in ... move to 21 by 2009. The increase is a ...
Cached Biology Technology:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross to Join Lifetime Networks and Members of Congress From Both Parties at Capitol Hill Press Conference 2Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross to Join Lifetime Networks and Members of Congress From Both Parties at Capitol Hill Press Conference 3Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability 2Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability 3Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 2Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 3
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Earth, their altitude isn,t the only thing that dropstheir ... hypotension, occurs in up to half of those astronauts ... nearly all astronauts after long-term missions (four to six ... FASEB Journal ( http://www.fasebj.org ) solves the ...
... on the banks of the Elbe are not a common ... part of European wildlife, when mega-fauna such as woolly mammoths ... in Boreas , believe that the changing climate during ... to pygmy sizes before driving them to warmer climes. ...
... Copenhagen, Denmark Data publishers should have the option ... to a discussion paper commissioned by the Global Biodiversity ... a set of recommendations made by Mark Costello and ... Rights in advancing biodiversity data publication , freely ...
Cached Biology News:Why astronauts experience low blood pressure after returning to Earth from space 2Did the changing climate shrink Europe's ancient hippos? 2Peer review option proposed for biodiversity data 2
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
PPIF Antibody...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Biology Products: